Washington, Oct. 21 -- OpenAI has acquired Orchestra Bio, a platform that helps biopharmaceutical companies coordinate drug development, as it looks to combine its artificial intelligence (AI) models with tools that manage the complex process of turning scientific discoveries into new medicines.

The acquisition will bring Orchestra Bio's team and technology together with OpenAI's Rosalind, a suite of AI models and tools designed for life sciences research. The combined platform aims to help scientists connect research findings with experiments, studies and decisions needed to advance potential treatments.

OpenAI said developing a new medicine takes roughly 10 to 15 years on average, from the discovery of a biological target to regulator...